Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine and Remifentanil on Carotid Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting adult patients (age \>50 years) undergoing carotid endarterectomy with general anesthesia.~Exclusion Criteria:~* Receiving another alpha 2-adrenoreceptor agonist;~* Contraindication to dexmedetomidine, including allergy;~* Current hepatic disease (liver function tests \> twice upper limit of normal);~* Renal insufficiency, as defined by a creatinine \> 2.0 mg/dL;~* Mentally impairment, including dementia or delirium;~* Heart block ;~* Sick sinus syndrome;~* Atrial fibrillation with a low ventricular response (\< 50 bpm);~* Absolute or relative hypovolemia;~* Prior stroke;~* Severe left-ventricular dysfunction

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.

Based on this trial design, predict the completion outcome and termination type (if applicable).